SLC5A2 and chronic kidney disease: The study evaluated the efficacy and safety of the soluble guanylate cyclase activator runcaciguat in CKD patients with atherosclerotic cardiovascular disease or heart failure, with or without type 2 diabetes (T2D), all receiving maximally tolerated doses of renin-angiotensin system inhibitors (with or without SGLT2 inhibitors).